| Chen, Keneng |
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 663 | RoW | Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel | Shanghai Junshi Bioscience Co., Ltd. | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 05/27 | 05/27 | | |
| Gao, Shugeng |
NCT03349203: Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Icotinib, Conmana | Betta Pharmaceuticals Co., Ltd. | EGF-R Positive Non-Small Cell Lung Cancer | 02/22 | 12/23 | | |
NCT03749213: Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Icotinib, Conmana | Betta Pharmaceuticals Co., Ltd. | EGF-R Positive Non-Small Cell Lung Cancer | 02/22 | 12/24 | | |
NCT04390958: Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 70 | RoW | nab-paclitaxel, Cisplatin, Capecitabine | Chinese Academy of Medical Sciences | Esophageal Squamous Cell Carcinoma | 06/22 | 12/22 | | |
NCT06163729: Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 68 | RoW | Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Gastroesophageal Junction Adenocarcinoma (Siewert II-III) | 05/25 | 05/28 | | |
NCT05913089: A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 58 | RoW | TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 06/26 | 12/26 | | |
NCT04460066: A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. |
|
|
| Active, not recruiting | 1/2 | 70 | RoW | anti-PD-L1 antibody, ZKAB001, Socazolimab Injection, albumin bound paclitaxel, ABRAXANE, cisplatin, placebo, radical resection of esophageal carcinoma | Lee's Pharmaceutical Limited | Esophageal Cancer | 12/21 | 07/23 | | |
| Recruiting | N/A | 4000 | RoW | Neoadjuvant immunotherapy, Immune checkpoint inhibitors, Other drugs for neoadjuvant treatment, Other drugs | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | NSCLC | 03/26 | 12/34 | | |
| Recruiting | N/A | 20000 | RoW | Sublobar resection, Lobectomy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Lung Cancer | 03/26 | 12/34 | | |
